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Background: Diagnosis of cardiac masses is still challenging by echocardiography and distinguishing tumors from
thrombi has important therapeutical implications. We sought to determine the diagnostic value of real-time perfusion
echocardiography (RTPE) for cardiac masses characterization.
Methods: We prospectively studied 86 patients, 23 with malignant tumors (MT), 26 with benign tumors (BT), 33 with
thrombi and 6 with pseudotumors who underwent RTPE. Mass perfusion was analyzed qualitatively and blood flow
volume (A), blood flow velocity (β), and microvascular blood flow (A x β) were determined by quantitative RTPE.
Results: Logistic regression models showed that the probability of having a tumor increased by 15.8 times with a
peripheral qualitative perfusion pattern, and 34.5 times with a central perfusion pattern, in comparison with the
absence of perfusion. Using quantitative RTPE analysis, thrombi group had parameters of blood flow lower than tumor
group. A values for thrombi, MT, and BT were 0.1 dB (0.01-0.22), 2.78 dB (1–7) and 2.58 dB (1.44-5), respectively; p < 0.05,
while A x β values were 0.0 dB/s−1 (0.01–0.14), 2.00 dB/s−1 (1–6), and 1.18 dB/s−1 (0.52–3), respectively; p < 0.05. At peak
dipyridamole stress, MT had greater microvascular blood volume than BT [A = 4.18 dB (2.14-7.93) versus A = 2.04 dB
(1.09-3.55); p < 0.05], but no difference in blood flow [Axβ = 2.46 dB/s−1 (1.42–4.59) versus Axβ = 1.55 dB/s [1] (0.51-4.08);
p = NS]. An A value >3.28 dB at peak dipyridamole stress predicted MT (AUC = 0.75) and conferred 5.8-times higher
chance of being MT rather than BT.
Conclusion: RTPE demonstrated that cardiac tumors have greater microvascular blood volume and regional blood
flow when compared with thrombi. Dipyridamole stress was useful in differentiating MT from BT.
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Cardiac masses are still a challenging issue during trans-
thoracic echocardiography and can mainly be classified
as tumors, thrombi or pseudotumors. Primary cardiac
tumors are rarely found (0.001%) [1]. Histologically, 75%
of tumors are benign, while 25% are malignant [2]. Sec-
ondary cardiac tumors or metastases are at least 100
times more frequent than primary tumors [3]. Intracardiac
thrombi are blood clots that may also be erroneously de-
tected as tumors and occur typically in areas of blood sta-
sis, while pseudotumors are normal variations of cardiac
structures, which can be confounded with other forms of* Correspondence: jeane.tsutsui@incor.usp.br
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unless otherwise stated.cardiac masses. The etiology of a cardiac mass is crucial
for therapeutic management, however they still pose a
significant challenge in the clinical practice; also, an ex-
peditious determination of cardiac masses nature has im-
portant practical implications in the clinical management
of patients. The analysis of vascularity of these structures
may be important for this purpose, and real-time perfu-
sion echocardiography (RTPE) is an emerging approach
that can be used to evaluate vascularity.
RTPE has been demonstrated to be a useful technique
for the quantification of myocardial perfusion and deter-
mination of myocardial blood flow reserve [4-7]. Case
reports and a single center study with a small sample of
16 patients have shown the possibility of evaluating
vascularization of cardiac masses aiming to distinguish. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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from thrombi [8-14].
In this study, we sought to demonstrate the diagnostic
value for characterization of cardiac masses through
qualitative and quantitative analyses of RTPE.
Methods
Study patients
From July 2004 to October 2008, we prospectively studied
107 patients with cardiac masses detected by transthoracic
echocardiography who underwent RTPE and subsequent
diagnostic investigation of mass etiology. The study proto-
col was approved by the Ethical Committee of the Univer-
sity of São Paulo Medical School, and all patients provided
written informed consent to participate. Exclusion criteria
were pregnancy or breast feeding, intracardiac shunt,
refusal or inability to sign the informed consent, severe
obstructive pulmonary disease, second or third-degree atrio-
ventricular block and history of allergy to components of
the echocardiographic contrast agents. Patients in whom
the diagnosis of cardiac mass could not be reached based
on results of pathology, clinical data and other imaging
technique (magnetic resonance imaging or computed
tomography), were also excluded.
Real-time perfusion echocardiography
After collecting the clinical history, a complete echocar-
diographic study was performed according to the recom-
mendations of the American Society of Echocardiography
[15]. Images were acquired with commercially avail-
able ultrasound systems (SONOS 5500 and IE33, Philips
Medical Systems, Bothell, Washington, USA) equipped
with S3 wide band transducer and contrast echo software
with low mechanical index imaging.
Analysis of cardiac mass localization, size, quantity,
echogenicity, mobility, relationships with adjacent struc-
tures and hemodynamic impairment was performed be-
fore contrast infusion. Imaging was performed in the
apical 2-, 3- and 4-chamber views using power modula-
tion mode with a mechanical index of 0.2, frame rate
25–30 Hz and continuous intravenous infusion of either
lipid-encapsulated microbubbles Definity® (Lantheus Medical
Imaging, Inc., N. Billerica, Massachusetts, USA) or PESDA
(perfluorocarbon-exposed sonicated dextrose albumin).
The formulation of PESDA has been described elsewhere
[16]. Microbubble destruction was achieved using a packet
of five high-intensity (mechanical index 1.5) pulses (flash).
One vial of ultrasound contrast agent Definity® was diluted
in 60 mL saline solution and infused continuously into the
right antecubital vein after an initial bolus dose of 3 mL.
PESDA was administered intravenously in a continuous
fashion at a rate of 2–5 ml/min and prepared by diluting a
suspension of 0.1 ml/kg of contrast in 80 ml of 5%
dextrose.Optimal gain and compression were obtained, and ultra-
sound beam focus was adjusted below the region of interest
level. Image acquisition at baseline was obtained soon after
optimization of settings and as soon as contrast opacifica-
tion of the left ventricular cavity was considered homoge-
neous. A packet of five high intensity (mechanical index
1.5) flashes was manually deflagrated at a maximal visual
contrast intensity to achieve microbubble destruction
within the myocardium and cardiac masses. Contrast re-
plenishment within the myocardial structures and cardiac
masses was analyzed in low mechanical power (0.2) myo-
cardial perfusion images including at least 15 cardiac cy-
cles after the flash. Patients who agreed to undergo stress,
were ≥18 years old and had no contraindication to dipyr-
idamole underwent dipyridamole stress after acquisition
of baseline images. A total dose of 0.84 mg/Kg of dipyrid-
amole was infused during 10 minutes (peak). At the end
of dipyridamole infusion, a second acquisition of images
was performed using the same settings [17].
Continuous cardiac monitoring with one electrocardio-
graphic lead, blood pressure, heart rate and 12-lead electro-
cardiography were registered at the 4th and 10th minutes
after dipyridamole infusion, and after the test was termi-
nated. After acquisition of peak images patients received
aminophylline and were observed at rest for 30 minutes,
until they returned to baseline conditions.
Qualitative analysis of mass perfusion
Each set of digital images was reviewed by a sole experi-
enced and independent observer (EKU), blinded to other
study data. Starting from the first frame after the ultra-
sound destruction of microbubbles, cardiac masses were
qualitatively analyzed during optimal cavity contrast en-
hancement based on a visual assessment of mass contrast
enhancement. This assessment included the presence of
perfusion, the velocity of perfusion replenishment after
flash impulse, and the pattern of perfusion in the mass. A
scoring system was established by considering the follow-
ing parameters:
– Mass perfusion: 0 – perfusion absent; 1 – mild
perfusion; 2 – moderate perfusion; 3 – intense
perfusion;
– Replenishment perfusion velocity (post flash): 0 –
perfusion absent; 1 – slow replenishment (some
perfusion in the mass visualized 5 cardiac beats after
flash); 2 – fast perfusion (some perfusion in the
mass visualized before 5 cardiac beats after flash);
– Perfusion pattern: 0 – perfusion absent; 1 –
peripheral perfusion (perfusion predominantly in the
periphery of the mass, defined as its half external
part); 2 – central perfusion (perfusion detected in
the entire mass, including more than half internal
part of the mass) (Figure 1A);
Figure 1 Qualitative analysis of mass perfusion demonstrating examples of perfusion pattern (A) and areas of necrosis (B). LA = left atrium;
RA = right atrium; LV = left ventricle; RV = right ventricle; M = cardiac mass.
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specific region of the mass with perfusion around it):
0 – absent; 1 – present (Figure 1B).
Quantitative determination of mass perfusion
Off-line image analysis for perfusion was performed using
commercially available software (Q-lab 5.0 Advanced
Quantification Software – Philips Medical Systems, Bothell,
WA, USA). Regions of interest were manually traced on
the largest possible sample, in the planes where images of
interest would be best visualized in end-systolic frames
during baseline and, in those patients who underwent di-
pyridamole, at peak stress. Images frames were selected
after 10 high-mechanical index frames (flashes), at the
peak T-wave on the electrocardiogram, with careful exclu-
sion of large vessels or areas of no perfusion. In addition,
mass edges and pedicles were avoided.
Acoustic intensity curves were built in an exponential
function for analysis of 10 cardiac cycles on average for
each sequence of images, starting from the flash, until
the cardiac mass was completely replenished by contrast
(Figure 2). Peak signal intensity plateau (A, dB) and sig-
nal intensity rate of rise (ß, s−1) – that is proportional to
blood flow velocity - were calculated automatically by
the software. To originate an index of mass microvascu-
lar blood flow, the product of A and ß was calculated
[4]. For patients who underwent dipyridamole stress,
mass blood flow reserve (Ax ß), and mass blood flow re-
serve (A) were calculated as the ratio of hyperemic to
baseline parameter.Diagnostic confirmation of cardiac masses
Diagnostic determination of cardiac masses was performed
by anatomical pathology in patients who underwent sur-
gery or, in those who died, by autopsy [2]. The diagnosis of
rhabdomyomas was confirmed by other cardiovascular im-
aging modality (magnetic resonance imaging or computed
tomography), clinical association with tuberous sclerosis
and serial echocardiographic demonstration of mass re-
gression. The diagnosis of lipoma was performed by biopsy
or magnetic resonance imaging with fat saturation ap-
proach. The diagnosis of cardiac thrombi was performed
based on history and clinical presentation, including atrial
flutter, atrial fibrillation, atrial dilatation, valvar stenoses
and areas of left ventricular akinesia or diskinesia, associ-
ated with serial echocardiography findings of thrombus
resolution after anticoagulation. Pseudotumor was defined
as an anatomical variation or other cardiac abnormality
(megaesophagus, endomyocardialfibrosis, abscess) not
characterized as a cardiac tumor [18].
Statistical analysis
All the variables were descriptively analyzed. Quantita-
tive variables were analyzed by observing minimum and
maximum values, and by calculating means, standard
deviations and quartiles (percentile 25, median and per-
centile 75). Absolute and relative frequencies of qualita-
tive variables were calculated. Means of groups were
compared using unifactorial variance analyses, multiple
comparisons were done with Bonferroni’s test. Kruskal-
Wallis nonparametric test was used for variables with
Figure 2 Images from real-time perfusion echocardiography (upper panels) in apical 4-chamber view in a patient with a malignant tumor in the
left atrium. Image at left demonstrates the flash impulse high mechanical index followed by post-flash image (middle) and replenishment by contrast
(image at right) with region of interest (ROI) manually traced in the tumor. Lower panel shows the time-intensity curve obtained by quantification
software with estimation of myocardial blood volume at peak intensity (A), blood flow velocity (β) and regional blood flow (A x β). Yellow curve was
defined by measurements of intensity at each time interval while red curve corresponded to exponential fitted time-acoustic intensity.
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comparisons Dunn’s test was used.
Homogeneity between proportions was tested using
chi-square or Fisher’s exact test (whenever expected fre-
quencies were smaller than 5). Analysis of variance with
repeat measures checked the behavior of groups along
evaluations. For variables considered not normally dis-
tributed we used Wilcoxon’s nonparametric test. Cut-off
values of variables were obtained using ROC (receiver-
operator characteristic) curves. Intraobserver concord-
ance was evaluated using Kappa’s coefficient.
Significance level was established at 5%.
Results
Out of 107 initially enrolled patients, 21 were excluded
because there was no definitive diagnostic confirmation
of cardiac mass etiology. The final population consisted
of 86 patients with mean age 49.3 ± 16.5 years, 49 (57%)female. Twenty-three (27%) patients had malignant (pri-
mary or secondary) tumors, 24 (28%) benign tumors, 33
(38%) thrombi, and 6 (7%) pseudotumors. The charac-
teristics of patients and types of tumors are described in
Tables 1 and 2. Localization and distribution of cardiac
masses are seen in Figure 3. A total of 5 patients had
more than one cardiac mass (2 patients with thrombi, 2
patients with rhabdomyoma and 1 patient with primary
cardiac lymphoma). All the remaining patients had only
1 cardiac mass. Mean area size of malignant tumors was
16.1 cm2 (4.1 cm2 to 48.5 cm2), of benign tumors was
5.5 cm2 (1.9 cm2 to 40.1 cm2) and of thrombi was 6.4
cm2 (1.2 cm2 to 32.2 cm2).
Qualitative analysis of mass by RTPE
In all patients cardiac mass was evaluated by qualitative
RTPE. Distribution of cardiac masses according to quali-
tative perfusion scores is displayed in Table 3. Analysis
Table 1 Clinical characteristics of patients with malignant tumors, benign tumors, thrombi and pseudotumors
Variables Malignant (n = 23) Benign (n = 24) Thrombi (n = 33) Pseudotumors (n = 6) P
Age (years) 45.7 ± 19.2 46.8 ± 19.3 53.0 ± 16.2 52.5 ± 11.0 †
Female gender 12 (52.2%) 16 (64%) 17 (51.5%) 4 (57.1%) †
Weight (Kg) 69.2 ± 20.6 63.0 ± 20.0 63.11 ± 11.5 77.7 ± 21.3 †
Height (cm) 165.6 ± 12.2 158.9 ± 13.7 164.0 ± 9.2 163.2 ± 10.1 †
Body mass index (Kg/m2) 24.8 ± 5.3 24.4 ± 6.2 23.4 ± 3.4 29.1 ± 7.1 †
Cardiovascular history
Hypertension 7 (30.4%) 13 (52%) 15 (45.5%) 3 (42.8%) †
Diabetes 4 (17.4%) 4 (16%) 4 (12.1%) 2 (28.6%) †
Coronary artery disease 1 (4.3%) 3 (12%) 9 (27.3%) 1 (14.3%) †
Dilated cardiomyopathy 0 1 (4%) 9 (27.3%) 2 (28.6%) *
Congestive heart failure 3 (13.0%) 4 (16%) 17 (51.5%) 3 (42.8%) *
Atrial fibrillation 1 (4.3%) 1 (4%) 4 (12.1%) 0 †
Embolic event 2 (8.7%) 0 4 (12.1%) 0 †
Cerebrovascular accident 1 (4.3%) 4 (16%) 3 (9.0%) 1 (14.3%) †
Valvular heart disease 1 (4.3%) 1 (4%) 9 (27.3%) 0 *
Signs and symptoms
Dyspnea 15 (65.2%) 5 (20%) 22 (66.7%) 3 (42.8%) †§
Fever 1 (4.3%) 0 2 (6.0%) 1 (14.3%) †
Peripheral edema 8 (34.8%) 0 10 (30.3%) 2 (28.6%) *§
Dysphagia 4 (17.4%) 1 (4%) 0 0 *
Chest pain 7 (30.4%) 5 (20%) 3 (9.0%) 1 (14.3%) †
Syncope 1 (4.3%) 1 (4%) 0 0 †
Odynophagia 3 (13.0) 0 0 0 *§
Weight loss 12 (52.2%) 0 7 (21.2%) 0 *§
Lipothymia 4 (17.4%) 2 (8%) 2 (6.0%) 0 †
† = not significant between groups; * = p < 0.001 between malignant tumors, benign tumors, thrombi and pseudotumors; § = p < 0.05 between malignant tumors
and benign tumors.
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groups (thrombi and tumor) shows that thrombi group
had higher number of cases with zero perfusion score, in
contrast with tumor group, in which the prevailing score
was 1 (mild perfusion). Similarly, replenishment perfu-
sion velocity in thrombi group was mostly equal to zero,
while in tumor group the most frequent score was 1
(slow replenishment). The Kappa concordance coeffi-
cient for each variable shows that there was good correlation
of scores with type of cardiac mass (tumor or thrombi) for
mass perfusion (0.65; p < 0.001); replenishment perfusion
velocity (0.643; p < 0.001) and areas of necrosis (0.468; p <
0.001). The correlation for perfusion pattern was subopti-
mal (0.379; p < 0,001). Logistic regression models showed
that the probability of having a tumor increased by 15.8
times with a peripheral perfusion pattern, and 34.5 times
with a central perfusion pattern, in comparison with the
absence of perfusion. There was no association between
perfusion pattern (either central or peripheral) and type oftumor. When areas of necrosis (absence of perfusion in
one specific region of the mass with perfusion around it)
were present, the probability of having a tumor was 6.7
times higher than when these were absent. Intraobserver
variability was 20% considering perfusion score and perfu-
sion velocity; 25% for areas of necrosis, and 45% for perfu-
sion pattern. Intraobserver overall variability was 35%.
Quantitative analysis of mass by RTPE
Quantitative analysis was feasible in 73 (85%) patients.
In 13 (15%) patients quantitative analysis was not possible
due to technical difficulties, such as reduced mass size,
excessive mass mobility (n = 5), and presence of acoustic
shadowing over the mass (n = 8).
Among the 73 patients with quantitative analysis of car-
diac mass by RTPE, 23 (32%) had malignant tumors, 22
(30%) benign tumors, and 28 (38%) thrombi (Figure 4).
The group thrombi showed significantly lower micro-
vascular blood volume (A) and microvascular blood flow
Table 2 Types of cardiac masses in the study population
(also in Figure 2)
Malignant cardiac tumors
Primary
Primary cardiac lymphoma 3
Malignant pericardium mesothelioma 1
Secondary (metastases)
Mediastinal – Lymphoma 5
Mediastinal neoplasia of uncertain origin 1
Pulmonary adenocarcinoma 3
Not-small cell pulmonary carcinoma 1
Ductal breast carcinoma 1
Malignant testicular teratoma 1

















Abscess in right atrial lateral wall 1
Liver (diaphragm muscle paralysis) 1
Megaesophagus 1
Endomyocardiofibrosis 1
Caseous degeneration of mitral annulus 1
Anatomical variant (supra hepatic vein emerging into right
atrium and left superior vena cava in coronary sinus)
1
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lignant and benign tumors. A and A × β did not show any
significant differences between patients with malignant
and benign tumors (Table 4).
A ROC curve was drawn to obtain the best cutoff value
to help distinguish between thrombi and malignant/
benign cardiac tumors. The parameter microvascular
blood volume (A) showed an area under the curve (AUC)
of 0.94. Thus, the A < 0.64 dB on RTPE predicts thrombuswith a 93% sensitivity, 89% specificity, 81% positive pre-
dictive value, 95% negative predictive value, and 85% ac-
curacy. The parameter microvascular blood flow (A × β)
showed an AUC of 0.93 as predictor of thrombus, with
93% sensitivity, 84% specificity, 78% positive predictive
value, 95% negative predictive value, and 87% accuracy
(Figure 5). A cardiac mass with a value A × β < 0.30 dB/s−1
on RTPE had 68-times higher chance of being a thrombus
rather than a malignant or benign tumor.
Analysis of blood flow reserve by RTPE
Studies with dipyridamole for evaluation of tumor re-
serve was completed in 32 (44%) patients, 14 (44%) from
the malignant tumor group, 10 (31%) from the benign
tumor group, and 8 (25%) who had thrombi (Figure 4).
The remaining 41 patients (56%) did not receive dipyrid-
amole because they (or their primary physician) refused
(n = 14), had poor clinical condition (n = 24), or because
of their young age (n = 3). There were no significant al-
terations of systolic blood pressure and heart rate from
baseline to dipyridamole peak infusion. Values of quanti-
tative RTPE were very low in patients with thrombi. At
rest, A value was 0.1 dB (0.01-0.51) and at peak 0.21 dB
(0.01-0.73) while A × β value were 0.15 dB/s−1 (0.01-
0.47) and 0.09 dB/s−1 (0.01-0.32), respectively.
Among the 24 patients with cardiac tumors who under-
went dipyridamole study, two-dimensional echocardiog-
raphy did not differentiate a benign from malign tumor in
12 (50%) of patients. By qualitative analysis of RTPE, ab-
sence of perfusion (score 0) was observed in 2 patients
with malignant tumor; mild perfusion (score 1) was ob-
served in 6 (70%) patients with benign tumor and 12
(85%) patients with malignant tumor; moderate perfusion
(score 2) was observed in 2 patients (20%) with benign
tumor, and intense perfusion (score 3) was observed in 1
(10%) patient with benign tumor. By qualitative analysis,
we were not able to differentiate benign from malignant
tumors. Table 5 shows quantitative parameters at rest and
dipyridamole stress in patients with malignant and benign
tumors. No significant differences were found between
patients with benign and malignant tumors at baseline. At
dipyridamole stress, the group with malignant tumors evi-
denced greater microvascular blood volume (A) than the
group with benign tumors. No difference was evidenced be-
tween groups with malignant tumors and benign tumors
considering A reserve [0.91 (0.62-1.72) and 0.73 (0.5-1.48),
respectively; p =NS) and A × β reserve [1.18 (0.36-1.75)
and 1.1(0.56-1.82), respectively; p =NS]. Parameters of per-
fusion analyzed in the 24 patients with tumors showed
that when comparing only the groups with malignant and
benign tumors, the ROC curve of microvascular blood
volume (A) at the peak of dipyridamole stress showed an
AUC of 0.75. Therefore, A > 3.28 dB at peak dipyridamole
stress RTPE was predictive of malignant tumor. This value
Figure 3 Distribution of type of cardiac masses and its distribution in the 86 studied patients.
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ive value, 64% negative predictive value and 71% accuracy
to predict a malignant tumor. A cardiac tumor with A ≥
3.28 dB on dipyridamole stress RTPE had 5.8-times higher
chance of being malignant rather than benign tumor.
Discussion
The diagnosis of cardiac masses is challenging, given the
specific characteristics of the disease and the peculiarimages that they nearly always generate. Thanks to the
advances in cardiovascular imaging modalities in the last
50 years, there has been a noticeable improvement in
the knowledge about the prevalence and natural his-
tory of cardiac masses. Among these methods, echo-
cardiography has been demonstrated extremely useful
for evaluating patients with suspected cardiac masses.
Nevertheless, the great limitation of this method re-
sides in its inability to distinguish between thrombi and
Table 3 Qualitative real-time perfusion echocardiography scoring of cardiac masses (confirmed to be tumors or
thrombi) as assessed by the presence, velocity, and pattern of perfusion
Scores Groups Presence of perfusion Velocity Perfusion pattern Areas of necrosis
0 Thrombi 27 27 27 31
Tumors 11 9 9 37
1 Thrombi 6 0 4 2
Tumors 33 10 21 16
2 Thrombi 0 6 2 –
Tumors 6 34 23 –
3 Thrombi 0 – – –
Tumors 3 – – –
Scores: Perfusion: 0 (absence); 1 (mild); 2 (moderate); 3 (intense). Perfusion velocity: 0 (absence); 1 (fast replenishment); 2 (slow replenishment)). Perfusion
pattern: 0 (absence); 1 (peripheral); 2 (central). Areas of necrosis: 0 (absent); 1 (present).
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difference between thrombi and tumors is the intense
vascularity of the latter, the thrombi being avascularized
or with rare canaliculi inside them. Benign tumors have
scarce vascularity, while malignant tumors have abundant
neovascularization.Figure 4 Flow chart showing patients’ selection for qualitative and quantitRTPE is a modality that uses no ionizing agent, is versa-
tile and cost-effective study for the evaluation of myocar-
dial perfusion, therefore highly desirable for the evaluation
of cardiac mass. In the recent years, its diagnostic and
prognostic value has been established in patients with sus-
pected coronary artery disease [7,8,19-21]. Quantitativeative real-time perfusion echocardiography.
Table 4 Median and quartile values of quantitative perfusion variables in patients with malignant tumors, benign
tumors and thrombi
Variable Malignant tumors (n = 23) Benign tumors (n = 22) Thrombi (n = 28)
P25 MEDIAN P75 P25 MEDIAN P75 P25 MEDIAN P75 p
A (dB) 1.31 2.78 7.0 1.24 2.58 4.55 0.01 0.08 0.22 *†
Ax β (dB/s−1) 0.99 2.0 5.58 0.45 1.18 3.4 0.01 0.03 0.14 *†
A: Blood volume; A × β: Regional microvascular blood flow.
* = p < 0.001 between tumors and thrombi; † = not significant between malignant tumors and benign tumors.
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from observer experience and allows for determining
myocardial flow reserve. This technique, although time-
consuming was shown useful for evaluating different clin-
ical conditions with alteration in microvascular blood
flow [17,22-25]. The angiogenic response of tumors varies
according to the existing circulation [26,27]. Neovasculari-
zation may have an increase in diameter or length, thus
varying its internal resistance and consequently the local
tumor perfusion. Besides that, there are tumors which re-
ceive a direct irrigation from coronary arteries, as it was
the case in two myxomas and one paraganglioma among
our study patients.
Qualitative analysis of perfusion echocardiography is
easy, although its reproducibility is problematic as aFigure 5 Receiver operator curves for A (blue line) and Axβ (green line) vareliable method for differentiating cardiac masses. Quan-
titative analysis of RTPE has the potential to enable the
differential diagnosis of tumor from thrombi with higher
accuracy. In the present study, masses with microvascu-
lar volume (A) < 0.64 dB and microvascular blood flow
(A × β) < 0.30 dB/s−1 predicted thrombi with accuracy of
85% and 87%, respectively. In the literature we found only
one report with similar results [9], which was limited to
quantification of perfusion of only nine tumor cases, since
the other seven masses were thrombi. Parameters of
blood flow were compared between the mass and adja-
cent myocardium.
Of note, although there are previous studies demon-
strating the value of contrast echocardiography in patients
with cardiac masses [8-12,28], this is the first time in thelues for detection of tumors and thrombi groups.
Table 5 Median and quartile values of quantitative perfusion variables at baseline and dipyridamole stress, in patients
with malignant and benign tumors
Variable Malignant tumors (n = 14) Benign tumors (n = 10)
P25 MEDIAN P75 P25 MEDIAN P75 P
A (dB) rest 1.7 3.11 8.4 1.11 1.88 4.55 †
Axβ (dB/s−1) rest 1.11 1.88 4.55 0.49 1.11 4.52 †
A (dB) - stress 2.14 4.18 7.93 1.11 2.69 4.26 §
Axβ (dB/s−1) - stress 1.42 2.46 4.59 0.55 1.55 5.5 †
A: Blood volume; Axβ: Regional microvascular blood flow.
† = not significant between malignant tumors and benign tumors; § = p < 0.05 between malignant tumors and benign tumors.
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high number of patients for evaluating cardiac masses and
we demonstrated it to be a safe method. Dipyridamole
stress significantly contributed for differentiating malig-
nant from benign cardiac tumors. There was an increase
in the value of microvascular blood volume (A) in the
group with malignant tumors as compared with that of
benign tumors. Cardiac tumors presenting a value A >
3.28 dB in dipyridamole stress RTPE had 5.8-times higher
chance of being a malignant rather than a benign tumor.
It is well known that malignant tumors have intense
neovascularization, vessels with thin, tortuous walls with
greater variability in diameter. However, until now there
was no study in the literature using dipyridamole in pa-
tients with cardiac tumors with the purpose of evaluat-
ing tumoral perfusion vascular reactivity. Hence, we
believe that these data may serve as the initial trigger
for future investigation with new quantification techniques
as parametric imaging in order to better define tumoral
characteristics.
Study limitations
Although one potential limitation of the present study is
the great variability in etiology of tumors, the distribu-
tion among groups was a proportionate one (28% benign
cardiac masses, 38% thrombi, and 27% malignant tu-
mors). Not all patients underwent dipyridamole infusion
because of refusal to undergo stress or clinical contra-
indication to exam. Therefore, one could argue that this
analysis was incomplete. We would like to note that the
total number of patients evaluated by dipyridamole stress
RTPE was still reasonable (32) considering the specific pa-
tient population studied and the criteria for inclusion in
the study. One possible limitation is heterogeneity in
quantification data because of the use of different contrast
agents (PESDA and Definity). However, we have recently
published studies of myocardial perfusion quantification
showing the diagnostic and prognostic value of RTPE
using both contrast agents in different patient population
[17,25]. Another limitation is the high intraobserver vari-
ability found in our study. This probably expresses the
difficulty of analyzing perfusion in cardiac tumors dueto their amorphous, heterogeneous structure and calls
for the development of a more observer independent
tool for its analysis. Finally, in some cases thrombi or tu-
mors could have been diagnosed with very high degree
of probability based solely on their features in stand-
ard echocardiography. In these cases perfusion contrast
echocardiography did not add value over clinical and two-
dimensional echocardiography.
Conclusion
RTPE allowed for demonstration that cardiac tumors
have greater microvascular blood volume and regional
blood flow in comparison with thrombi. Qualitative ana-
lysis is a fast diagnostic approach to diagnose thrombi,
however it is still poorly reproducible. Dipyridamole stress
quantitative RTPE was useful for differentiating malignant
from benign tumors.
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